Home > Annual Financials > LYKA LABS

LYKA LABS Financial Statement Analysis
[BOM: 500259|NSE : LYKALABS]

The Revenues of LYKA LABS have decreased by -7.26% YoY .
The Earnings Per Share (EPS) of LYKA LABS has decreased by Negative YoY.
COMMUNITY POLL
for LYKA LABS
Please provide your vote to see the results

LYKA LABS Last 5 Annual Financial Results
[BOM: 500259|NSE : LYKALABS]

ConsolidatedMar2026
Mar2025
Mar2024
Mar2023
Mar2022
Revenues ₹128 Cr₹138 Cr₹111 Cr₹93 Cr₹194 Cr
Expenses ₹132 Cr₹121 Cr₹95 Cr₹76 Cr₹93 Cr
Operating Profit (Excl OI) ₹-3.49 Cr₹18 Cr₹16 Cr₹17 Cr₹101 Cr
Other Income ₹3.50 Cr₹2.23 Cr₹1.47 Cr₹3.40 Cr₹2.09 Cr
Interest ₹3.33 Cr₹2.27 Cr₹4.89 Cr₹12 Cr₹20 Cr
Depreciation ₹8.46 Cr₹6.77 Cr₹13 Cr₹14 Cr₹17 Cr
Profit Before Tax ₹-12 Cr₹11 Cr₹-0.93 Cr₹-13 Cr₹59 Cr
Profit After Tax ₹-10 Cr₹7.93 Cr₹-2.62 Cr₹-13 Cr₹38 Cr
Consolidated Net Profit ₹-10 Cr₹8.01 Cr₹-2.49 Cr₹-13 Cr₹39 Cr
Earnings Per Share (Rs)₹-2.81₹2.24₹-0.75₹-4.30₹13.59
PAT Margin (%)-8.125.73-2.36-14.1319.81
ROE(%)-10.649.71-6.02-63.630.00
ROCE(%)-5.9610.013.26-1.0056.68
Total Debt/Equity(x)0.530.360.962.589.76

Key Financials

Market Cap : ₹ 224.4 Cr
Revenue (TTM) : ₹ 128.4 Cr
Net Profit(TTM) : ₹ -10.4 Cr
EPS (TTM) : ₹ -2.9
P/E (TTM) : -

Industry Peers & Returns1W1M1Y
LYKA LABS -5.6% -15.8% -43.3%
SUN PHARMACEUTICAL INDUSTRIES 1.8% 5.6% 16.7%
DIVIS LABORATORIES 0.5% 13.1% 10.9%
TORRENT PHARMACEUTICALS -2.7% 5.1% 42.4%
CIPLA 2.1% -0.6% -4.5%
DR REDDYS LABORATORIES -4% -17.5% -8.6%
MANKIND PHARMA 2.9% 5.4% -3.6%
LUPIN -0.5% -0.5% 25.4%
ZYDUS LIFESCIENCES -2.7% -2% 14.3%


LYKA LABS Revenues
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

-7.26 %

5 Yr CAGR

-9.81 %

Years Revenues % Change
Mar2026 ₹128 Cr
-7.26
Mar2025 ₹138 Cr
24.55
Mar2024 ₹111 Cr
19.47
Mar2023 ₹93 Cr
-52.05
Mar2022 ₹194 Cr -


LYKA LABS Operating Profit
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years Operating Profit % Change
Mar2026 ₹-3.49 Cr
Negative
Mar2025 ₹18 Cr
14.20
Mar2024 ₹16 Cr
-6.74
Mar2023 ₹17 Cr
-83.35
Mar2022 ₹101 Cr -

Operating Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years Operating Margin% % Change
Mar2026 -2.71%
Negative
Mar2025 12.95%
-8.29
Mar2024 14.12%
-21.95
Mar2023 18.09%
-65.29
Mar2022 52.12% -

LYKA LABS Profit After Tax
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years Profit After Tax % Change
Mar2026 ₹-10 Cr
Negative
Mar2025 ₹8.01 Cr
Positive
Mar2024 ₹-2.49 Cr
Negative
Mar2023 ₹-13 Cr
Negative
Mar2022 ₹39 Cr -

PAT Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years PAT Margin(%) % Change
Mar2026 -8.12 %
Negative
Mar2025 5.73 %
Positive
Mar2024 -2.36 %
Negative
Mar2023 -14.13 %
Negative
Mar2022 19.81 % -

LYKA LABS Earnings Per Share (EPS)
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years EPS % Change
Mar2026 ₹-2.81
Negative
Mar2025 ₹2.24
Positive
Mar2024 ₹-0.75
Negative
Mar2023 ₹-4.30
Negative
Mar2022 ₹14 -

LYKA LABS Return on Capital Employed (ROCE)
[BOM: 500259|NSE : LYKALABS]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years ROCE % Change
Mar2026 -5.96%
Negative
Mar2025 10.01%
207.06
Mar2024 3.26%
Positive
Mar2023 -1%
Negative
Mar2022 56.68% -

LYKA LABS Share Price vs Sensex

Current Share Price : ₹62.0
Current MarketCap: ₹ 224.4 Cr
Updated EOD on :Jul 28,2026

Share Price Returns(%) 1 Week 1 Month 1 Year
LYKA LABS

-5.6%

-15.8%

-43.3%

SENSEX

-0.9%

-0.4%

-6.1%

LYKA LABS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about LYKA LABS Financials


How the annual revenues of LYKA LABS have changed ?

The Revenues of LYKA LABS have decreased by -7.26% YoY .

How the Earnings per Share (EPS) of LYKA LABS have changed?

The Earnings Per Share (EPS) of LYKA LABS has decreased by Negative YoY .